氨酸激酶向揭示了塔斯马尼亚魔鬼传染性癌症中的瘤性途径可塑性
Anna Schönbichler1, Anna Orlova1, Carmen Kreindl1
1Animal Breeding and Genetics, University of Veterinary Medicine Vienna, Vienna, 1210, Austria.
The EMBO journal
|November 3, 2025
概括
塔斯马尼亚魔鬼传染性癌症 (DFT1,DFT2) 对向治疗产生耐药性. 了解它们的适应信号通路对于开发有效的治疗方法和保护策略至关重要.
科学领域:
- 癌症生物学 癌症生物学
- 保护遗传学 保护遗传学
- 药理学 药理学是指药理学的学科.
背景情况:
- 可传播的癌症魔鬼面部瘤1 (DFT1) 和魔鬼面部瘤2 (DFT2) 威胁着塔斯马尼亚魔鬼种群.
- DFT1由ERBB信号驱动,而DFT2由PDGFRA信号驱动.
研究的目的:
- 为了研究DFT1和DFT2细胞系的激酶酸化概况.
- 了解对氨酸激酶抑制剂耐药性的机制.
- 为塔斯马尼亚魔鬼的保护策略和更广泛的癌症研究提供信息.
主要方法:
- 在DFT细胞系中分析酶酸化概况.
- 用氨酸激酶抑制剂对DFT细胞系进行长期治疗.
- 评估副本编号的变化和信号通路的激活 (ERBB,JAK/STAT).
主要成果:
- DFT1细胞通过信号可塑性快速逃避ERBB抑制.
- DFT2细胞对伊马替尼的抗性发展较慢,涉及拷贝数的改变和ERBB和JAK/STAT通路的激活.
- 针对ERBB和PDGFR的双重向显示了DFT1中的协同效应,并可能防止耐药性.
结论:
- 传染性癌症表现出显著的适应能力和信号可塑性.
- 了解耐药性机制对于开发针对DFT和人类癌症的有效疗法至关重要.
- 针对性治疗与预防耐药性的策略相结合,对于保护和治疗至关重要.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Rous Sarcoma Virus (RSV) and Cancer
6.2K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
6.2K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Mechanisms of Retrovirus-induced Cancers
6.8K
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
6.8K


